A comprehensive in-vitro investigation of a novel chemotherapy drug combination. In this study, we employed a well-controlled quantitative proteomics pipeline to examine the temporal molecular interactions between gemcitabine (Gem) and BGJ398 (infigratinib), a recently-approved pan-FGFR inhibitor, in a pancreatic ductal adenocarcinoma (PDAC) cell line.